‘Pharma companies make money on a new drug by selling a lot or charging a lot - but with antimicrobials neither is possible.’ - Andrew Bowskill #AAMRNet. Delinking funding from use is the only way to stimulate investment in new antimicrobials #MTPConnect #AMR #antimicrobials @drewabow.bsky.social

Australian universities urge Albanese to join New Zealand in $170bn Europe fund amid Trump attacks on education

Timely access to appropriate antimicrobials is essential for patient care, antimicrobial stewardship & minimising the risk of resistance - excellent summary of the issues here: amr.solutions/2025/04/07/y... Thanks to @johnhrexmd.bsky.social for highlighting our paper #AMR #AntibioticAccess #AMS 💊

The access pathway for unregistered medicines in Australia is used extensively to access antimicrobials, including for life-threatening infections Difficulty accessing appropriate antimicrobials is not only a problem affecting LMICs doi.org/10.1093/jaca... @nadinehillock.bsky.social

On average, 15–16 patients/day require an antibacterial not registered for use in Australia Highlights that new pathways are needed to register antibacterials for otherwise untreatable infections doi.org/10.1093/jaca... @jac-amr.bsky.social @drewabow.bsky.social @peripatetical.bsky.social #AMR

The survey closes Feb 28 2025 It is important many Australian researchers complete this survey to present as strong a voice as possible for #AMR to be central to the Strategy Thanks to @drewabow.bsky.social and AAMRNet for bringing this to our attention. Sign up to receive the AAMRNet newsletter